Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 5,257,389 shares of common stock, $0.0001 par value per share ("Common Stock"), of Tenax Therapeutics, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1") and separately managed accounts of ADAR1. Such securities may be deemed to be indirectly beneficially owned by ADAR1. In addition to the shares reported above, certain private investment funds managed by ADAR1 and separately managed accounts of ADAR1 hold pre-funded warrants exercisable for 59,073 shares of Common Stock and warrants exercisable for 31,096 shares of Common Stock. The shares of Common Stock issuable upon exercise of these warrants and pre-funded warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because each such warrant and pre-funded warrant is subject to a 4.99% beneficial ownership limitation. The percentage in box 11 is based on 37,423,917 shares of Common Stock outstanding as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 5,257,389 shares of common stock, $0.0001 par value per share ("Common Stock"), of Tenax Therapeutics, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1") and separately managed accounts of ADAR1. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1. In addition to the shares reported above, certain private investment funds managed by ADAR1 and separately managed accounts of ADAR1 hold pre-funded warrants exercisable for 59,073 shares of Common Stock and warrants exercisable for 31,096 shares of Common Stock. The shares of Common Stock issuable upon exercise of these warrants and pre-funded warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because each such warrant and pre-funded warrant is subject to a 4.99% beneficial ownership limitation. The percentage in box 11 is based on 37,423,917 shares of Common Stock outstanding as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:09/08/2026
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:09/08/2026
Exhibit Information

Exhibit A: Joint Filing Agreement


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT A